Case Report
Copyright ©The Author(s) 2016.
World J Clinical Cases. Sep 16, 2016; 4(9): 258-263
Published online Sep 16, 2016. doi: 10.12998/wjcc.v4.i9.258
Figure 3
Figure 3 Case 3. A: Before treatment, showing multiple pathological foci of hypermetabolic activity in local dense areas of subcutaneous fat (the largest are indicated by arrows, on the whole-body image as well) and pathological foci of fluorine-18 fluorodeoxyglucose uptake in the epiploon in the left mesogastric area (indicated by circles, on the whole-body image as well); B: After 3 cycles of FCM, showing resorption of all previously defined foci (including those in the greater omentum) but development of new ones in the subcutaneous tissue; C: After 3 cycles of GEM-P, showing marked improvement that was indicated by resorption of all previously defined foci. FCM: Fludarabine, mitoxantrone and cyclophosphamide; GEM-P: Gemcitabine, cisplatin and methylprednisolone.